Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Cancers
|
January 20, 2021
IFN-γ and CD38 in Hyperprogressive Cancer Development
Stefania Angelicola, Francesca Ruzzi, Lorena Landuzzi, et al.
NPJ Vaccines
|
April 27, 2026
HER-2 therapeutic vaccine is not hampered by concurrent HER-2 monoclonal antibody
Maria Sofia Semprini, Chiara Cappello, Laura Scalambra, et al.
Methods in Cell Biology
|
November 8, 2024
Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay
Francesca Ruzzi, Maria Sofia Semprini, Laura Scalambra, et al.
International Journal of Molecular Sciences
|
August 26, 2023
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
Francesca Ruzzi, Maria Sofia Semprini, Laura Scalambra, et al.
Cell Communication and Signaling : CCS
|
October 11, 2024
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?
Francesca Ruzzi, Chiara Cappello, Maria Sofia Semprini, et al.
Frontiers in Pharmacology
|
December 1, 2025
Development of cellular models expressing cynomolgus (<i>Macaca fascicularis</i>) HER2 for the functional evaluation of cross-reactive anti-human HER2 response
Chiara Cappello, Francesca Ruzzi, Julia Consoli, et al.
Biological Research
|
March 28, 2026
Alternatives for fetal bovine serum (FBS) and sustainability of milk derivatives in cell culture
Olga Maria Pittino, Maria Sofia Semprini, , et al.
Journal of Translational Medicine
|
January 30, 2025
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, et al.
Translational Lung Cancer Research
|
December 15, 2022
ADK-VR2, a cell line derived from a treatment-naïve patient with <i>SDC4-ROS1</i> fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
Francesca Ruzzi, Stefania Angelicola, Lorena Landuzzi, et al.
Biomedicines
|
October 27, 2022
Prevention and Therapy of Metastatic HER-2<sup>+</sup> Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine
Francesca Ruzzi, Arianna Palladini, Stine Clemmensen, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Cancers
|
January 20, 2021
IFN-γ and CD38 in Hyperprogressive Cancer Development
Stefania Angelicola, Francesca Ruzzi, Lorena Landuzzi, et al.
NPJ Vaccines
|
April 27, 2026
HER-2 therapeutic vaccine is not hampered by concurrent HER-2 monoclonal antibody
Maria Sofia Semprini, Chiara Cappello, Laura Scalambra, et al.
Methods in Cell Biology
|
November 8, 2024
Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay
Francesca Ruzzi, Maria Sofia Semprini, Laura Scalambra, et al.
International Journal of Molecular Sciences
|
August 26, 2023
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
Francesca Ruzzi, Maria Sofia Semprini, Laura Scalambra, et al.
Cell Communication and Signaling : CCS
|
October 11, 2024
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?
Francesca Ruzzi, Chiara Cappello, Maria Sofia Semprini, et al.
Frontiers in Pharmacology
|
December 1, 2025
Development of cellular models expressing cynomolgus (<i>Macaca fascicularis</i>) HER2 for the functional evaluation of cross-reactive anti-human HER2 response
Chiara Cappello, Francesca Ruzzi, Julia Consoli, et al.
Biological Research
|
March 28, 2026
Alternatives for fetal bovine serum (FBS) and sustainability of milk derivatives in cell culture
Olga Maria Pittino, Maria Sofia Semprini, , et al.
Journal of Translational Medicine
|
January 30, 2025
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, et al.
Translational Lung Cancer Research
|
December 15, 2022
ADK-VR2, a cell line derived from a treatment-naïve patient with <i>SDC4-ROS1</i> fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
Francesca Ruzzi, Stefania Angelicola, Lorena Landuzzi, et al.
Biomedicines
|
October 27, 2022
Prevention and Therapy of Metastatic HER-2<sup>+</sup> Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine
Francesca Ruzzi, Arianna Palladini, Stine Clemmensen, et al.
Page
of 2